AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
CHMP Pipeline Surge, NICE Threshold Jump, JCA Device Push
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Welcome to Access Brief, the daily AI podcast on HEAR, HTA, and Market Access. I'm Marcus with Sarah. Today, EMA's CHMP, eight medicine approval surge, nice threshold, jump to 35,000 pounds per Cali, and JCA's medical device push. Let's get into it.
SPEAKER_00EMA's CHMP had a packed May meeting. Eight medicines recommended for approval, including JASC ID for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. But the real standout is Vejoyce getting the first ever conditional marketing authorization for severe PIK3 CA-related overgrowth spectrum disorders.
SPEAKER_01First ever authorization for PROS is significant from an evidence perspective. Conditional approval suggests they're working with limited data sets, which makes the HTA pathway interesting. These ultra-rare conditions force adaptive evidence frameworks.
SPEAKER_00Exactly, and it signals EMA's willingness to move on rare diseases where traditional RCT designs fail. But here's where I push back. Conditional approval doesn't solve the commercial access problem. Payers still want robust economic evidence, and building that post-approval for a condition this rare is nearly impossible.
SPEAKER_01That's fair, but the regulatory signal matters for downstream HTA bodies. EMA's conditional approval creates momentum that national bodies can reference. The evidence bar shifts when you're addressing genuine unmet medical need.
SPEAKER_00Maybe, but we've seen conditional approval struggle at national level before. The evidence generation requirements post-approval often create more uncertainty, not less, especially for budget impact models.
SPEAKER_01Moving to NICE, they've confirmed cost effectiveness threshold changes, raising the standard range from 20,000 pounds, 30,000 to 25,000 pounds, 35,000 per cali. This isn't incremental adjustment, it's a structural shift that affects every future technology appraisal.
SPEAKER_00Finally, the 30,000 pound ceiling was becoming a bottleneck for innovative therapies. But I'm skeptical about the implementation timing and how this cascades through the NHS budget process. A 17% increase in willingness to pay thresholds without corresponding budget increases creates its own access problems.
SPEAKER_01The threshold increase reflects economic reality, healthcare inflation, opportunity costs of foregone treatments. From a methodological standpoint, this aligns nice closer to other major HTA bodies. The evidence requirements don't change, just the economic bar.
SPEAKER_00But that's exactly my concern. We're not seeing corresponding changes in evidence standards or budget processes. Higher thresholds without systematic budget reform just shifts the constraint elsewhere. Plus, this puts pressure on other European HTA bodies to follow suit, creating potential pricing arbitrage issues.
SPEAKER_01The EU Joint Clinical Assessment Framework is expanding into medical devices with approximately five assessments planned to start in June 2026. This builds on the cancer medicines and ATMP assessments that began in January 2025.
SPEAKER_00Medical device JCA is where the methodology really gets tested. Devices don't fit the pharmaceutical evidence model, shorter development cycles, iterative improvements, different regulatory pathways. The PICO frameworks that work for drugs fall apart with medical technology.
SPEAKER_01True, but that's exactly why JCA expansion into devices matters. It forces harmonized evidence standards across member states for technology assessment. The alternative is continued fragmentation where device manufacturers face 27 different evidence requirements.
SPEAKER_00I'm not convinced harmonization works for devices, software updates, learning curve effects, institutional implementation differences. These create genuine heterogeneity that centralized assessment can't capture. We might be forcing uniformity where variation is actually appropriate.
SPEAKER_01NICE also published guidance recommending semaglutide for cardiovascular risk reduction in patients with established CVD and obesity or overweight status. This expands the GLP1 access pathway beyond traditional diabetes and weight management indications.
SPEAKER_00This is the commercial breakthrough GLP1 manufacturers have been positioning for. Cardiovascular indication dramatically expands the eligible population and creates a different risk-benefit calculation for payers. But the budget impact is potentially massive. We're talking about fundamentally different population denominators.
SPEAKER_01The evidence base supports it though. Cardiovascular outcomes data for semaglutide is robust, and the risk reduction justifies the indication expansion from a clinical perspective.
SPEAKER_00Clinically, yes. Commercially, this creates a sustainability question for health systems. When you expand a high-cost therapy to cardiovascular prevention in overweight patients, you're potentially talking about millions of eligible patients across Europe. The economic modeling assumptions around treatment duration and adherence become critical.
SPEAKER_01Fair point, but that's a budget planning challenge, not an evidence quality issue. The HTA framework should assess clinical and economic value. Resource allocation decisions sit with payers and health systems.
SPEAKER_00These developments collectively show European HTA systems adapting to complex therapeutic landscapes, but the pace of change creates implementation gaps.
SPEAKER_01Agreed. Higher NICE thresholds, expanded JCA scope, and broader indication approvals signal methodological evolution, but the commercial and budget realities lag behind the evidence frameworks.no.